The Big Data of Drug Safety

At gift, FDA tracks those adverse events through a mongrel voluntary/mandatory reporting model which feeds premises into its FDA Adverse Event Reporting System (FAERS).

But across the last few years, FDA has expressed good in moving past individual reports surrounding patient experiences and moving toward “tumid data” approaches. Last year, FDA proposed a starting a~ surveillance program within its Office of Clinical Pharmacology (OCP) known in the manner that the Pharmacological Mechanism-Based Drug Safety Prediction (PMDSP) program.

The program, according to FDA, was to destroy data and recognize patterns through the use of technology in order to meet with as-yet unrecognized safety signals.


Photo Credit

Drug safety

As in good season as 1931 Hayek was endorsing many anti-secondary deflation schemes.

Recent Comments